OSE Immuno Shares Surge 13% to €4.91, Marking a 36% Weekly Gain

A Rebound Extending Post-FDA Momentum

The stock is currently priced at €4.91 after breaking through the upper Bollinger Band set at €4.53. It is trading at 121% of the band, indicating a strong overbought condition. The RSI at 62 is below the 70 threshold but is nearing a tense zone. The stock has significantly surpassed its short-term moving averages: the MM20 at €3.61 and the MM50 at €3.57 are both more than 36% below the current price. The MM200 at €5.07 remains 3.16% above the current price, marking the next graphical threshold on the upward path. The technical resistance identified at €4.43 was breached during the session. It is worth recalling that OSE Immuno had previously surged 19.74% on April 28 following an FDA decision granting orphan drug designation to Veloxis Pharmaceuticals' pegrizeprument for the prevention of cardiac graft rejection. Today's rise continues this upward trend.

Busy Schedule and Cash Reserves Under Scrutiny

The Nantes-based company, led by Markus Cappel, published its annual results for 2025 on April 30, showing a net loss of €37.7 million and operational revenues down to €2.7 million from €83.4 million a year earlier. The available cash reserves are expected to last until the beginning of Q4 2026, a key factor in the company's financial strategy. According to a publication in the BODACC on December 2, 2025, OSE Immunotherapeutics underwent a capital increase, a move that fits into the context of cash management discussed in the company's financial communications. The calendar remains packed: results from the Phase 2 TEDOVA trial, assessing Tedopi in ovarian cancer, are anticipated during an oral presentation at the ASCO 2026 congress in Chicago, from May 29 to June 2. Prior to this, the publication of the audited consolidated accounts is scheduled for May 28, followed by the general assembly on June 24. Despite the recent bullish sequence, the stock is still down 17.76% over the past year.